ITI Pharma and Healthcare Fund
Direct · GrowthAI Summary
ITI Pharma and Healthcare Fund has delivered strong returns, with a 1Y SIP XIRR of 20.63% and 3Y SIP XIRR of 21.13%, well ahead of the category averages of 14.1% and 16.82% respectively. On a lump-sum basis, the fund's 3Y CAGR of 20.25% dramatically outpaced the NIFTY 50's 7.75%, generating a 3Y alpha of 12.98%. Calendar year returns show strong up years (43.59% in 2024, 34.87% in 2023) but also negative years (-8.79% in 2025, -6.57% in 2022), reflecting sector cyclicality.
The fund exhibits low market sensitivity with a beta of 0.58-0.62 versus the NIFTY 50, and its downside capture of 47.67% (1Y) and 55.18% (3Y) is meaningfully below its upside capture, indicating favorable asymmetry. The maximum drawdown of -17.69% took 155 days to bottom and 364 days to recover, with two drawdown events exceeding 10%. Calmar ratios of 1.10 (1Y) and 1.24 (3Y) suggest solid risk-adjusted returns relative to drawdown severity.
The portfolio is concentrated in pharmaceuticals, with Sun Pharma (13.26%) and Divi's Labs (7.97%) as the top holdings, and the Pharma & Biotechnology sector accounting for 69.2% of NAV. Healthcare Services adds 21.1% through hospital operators like Apollo Hospitals (6.05%) and Max Healthcare (5.05%). With 36 total holdings, the fund is reasonably diversified at the stock level but highly concentrated at the sector level, as expected for a thematic offering.
The fund outperforms its category on the primary SIP XIRR metric by roughly 6.5 percentage points over 1Y (20.63% vs 14.1%) and 4.3 percentage points over 3Y (21.13% vs 16.82%). Positive alpha across all measured periods, from 12.98% over 3Y down to 0.78% over 15Y, shows consistent outperformance versus the NIFTY 50, though the alpha narrows over longer horizons. This suggests recent performance has been particularly strong relative to its longer-term track record.
This fund suits investors with high risk tolerance who understand sector concentration risk and want tactical or satellite exposure to the Indian healthcare theme, not core portfolio holdings. A time horizon of at least 5-7 years is advisable to ride out sector cycles, as evidenced by negative calendar years in 2022 and 2025. Investors should be comfortable with drawdowns exceeding 15% and should cap sectoral fund allocation to a modest share of their overall equity portfolio.
- SIP XIRR of 20.63% (1Y) and 21.13% (3Y) significantly exceeds category averages of 14.1% and 16.82%
- Favorable capture asymmetry with downside capture (47.67% at 1Y) well below upside capture (65.11%), plus double-digit alpha across all periods
- Low expense ratio of 0.47% for a sectoral fund and a diversified 36-stock portfolio led by quality names like Sun Pharma and Divi's Labs
- Heavy sector concentration with 69.2% in pharmaceuticals exposes investors to single-sector regulatory, pricing, and export-cycle risks
- Performance is cyclical, with negative calendar year returns in 2025 (-8.79%) and 2022 (-6.57%), and a maximum drawdown of -17.69% that took a full year to recover
Generated on 11-09-2026, 3:16 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.61 L | 20.6% | -15.6% | 72.3% |
| 3 Years | ₹36.00 L | ₹48.46 L | 21.1% | 6.0% | 37.7% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 20.6% | 14.4% | 14.1% | +6.2% |
| 3 Years | 21.1% | 11.1% | 16.8% | +10.0% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 19.5% | 16.7% | -9.3% | 62.2% | 0.64 | 2.56 | 77% | — | — |
| 3 Years | 21.9% | 21.6% | 17.6% | 26.9% | 8.52 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +11.16 | 0.58 | 65.1% | 47.7% | 12.2% | -2.9% |
| 3 Years | +12.98 | 0.62 | 74.3% | 55.2% | 20.3% | 7.8% |
| 5 Years | +8.43 | 0.58 | 64.9% | 50.9% | 14.6% | 5.9% |
| 7 Years | +5.05 | 0.58 | 64.9% | 50.9% | 10.2% | 4.2% |
| 10 Years | +2.62 | 0.58 | 64.9% | 50.9% | 7.1% | 2.9% |
| 12 Years | +1.70 | 0.58 | 64.9% | 50.9% | 5.8% | 2.4% |
| 15 Years | +0.78 | 0.58 | 64.9% | 50.9% | 4.7% | 1.9% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited | 13.26% |
| 2 | Divi's Laboratories Limited | 7.97% |
| 3 | Apollo Hospitals Enterprise Limited | 6.05% |
| 4 | Max Healthcare Institute Limited | 5.05% |
| 5 | Torrent Pharmaceuticals Limited | 4.84% |
| 6 | Cipla Limited | 4.43% |
| 7 | Dr. Reddy's Laboratories Limited | 4.41% |
| 8 | Laurus Labs Limited | 4.21% |
| 9 | Aurobindo Pharma Limited | 3.84% |
| 10 | Mankind Pharma Limited | 3.39% |